Table 1. Demographics, auto-antibodies and treatments.

	lSSc		dSSc
Variable	Estimate	Count	Estimate	Count
Proportion Female:Male	18.0∶1	18∶1	1.2∶1	6∶5
Modified Rodnan Skin Score	9.05±1.29	19	22.82±2.82	11
Severity Index	7.00±0.78	18	7.18±0.91	11
Activity Index	3.39±0.38	18	4.27±0.75	11
Duration of Disease	10.68±2.68 yr	19	2.91±0.48 yr	11
Age
Cases	58.53±2.50 yr	19	49.64±3.17 yr	11
Controls	59.42±2.53 yr	19	49.80±3.64 yr	10
Lung
ILD	47.4±11.5%	19	63.6±14.5%	11
PAH	47.4±11.5%	19	36.4±14.5%	11
FVC Predicted	86.6±4.5%	16	73.4±6.5%	11
DLCO Predicted	63.1±4.9%	19	64.8±8.3%	10
Telangiectasia	17.6±9.2%	17	20.0±12.6%	10
Digits
Raynaud’s	100%	18	100%	11
Active digital ulcers	35.3±11.6%	17	30.0±14.5%	10
No. of digits with active digits ulcers	0.71±0.28	17	0.88±0.48	9
Contracture of phalanges	41.2±11.9%	17	63.6±14.5%	11
Autoantibodies
ACA positive	15.8±8.4%	19	0%	11
ANA positive	84.2±8.4%	19	90.1±8.7%	11
Scl-70 positive	15.8±8.4%	19	72.7±13.4%	11
Treatment
Methotrexate	0%	19	18.2±11.6%	11
Cyclophosphamide	0%	19	45.5±15.0%	11

Values given as mean ± SE or proportion ± SE if a percentage is indicated.